These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 32859946)

  • 1. Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling.
    Hosseini I; Gadkar K; Stefanich E; Li CC; Sun LL; Chu YW; Ramanujan S
    NPJ Syst Biol Appl; 2020 Aug; 6(1):28. PubMed ID: 32859946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
    Munakata W; Izutsu K; Mishima Y; Nagai H; Ishihara Y; Suzumiya J; Kanakura Y; Nanki T; Miyake T; Kawasaki A; Yoshinaga T; Ishizawa K
    Jpn J Clin Oncol; 2023 Oct; 53(10):912-921. PubMed ID: 37486002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systems-based digital twins to help characterize clinical dose-response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL.
    Susilo ME; Li CC; Gadkar K; Hernandez G; Huw LY; Jin JY; Yin S; Wei MC; Ramanujan S; Hosseini I
    Clin Transl Sci; 2023 Jul; 16(7):1134-1148. PubMed ID: 36908269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Summary of a workshop on preclinical and translational safety assessment of CD3 bispecifics.
    Kamperschroer C; Shenton J; Lebrec H; Leighton JK; Moore PA; Thomas O
    J Immunotoxicol; 2020 Dec; 17(1):67-85. PubMed ID: 32100588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.
    Matasar M; Bartlett NL; Shadman M; Budde LE; Flinn I; Gregory GP; Kim WS; Hess G; El-Sharkawi D; Diefenbach CS; Huang H; To I; Parreira J; Wu M; Kwan A; Assouline S
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):240-253. PubMed ID: 38195322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma.
    Bender B; Li CC; Marchand M; Turner DC; Li F; Vadhavkar S; Wang B; Deng R; Lu J; Jin J; Li C; Yin S; Wei M; Chanu P
    Clin Transl Sci; 2024 Jun; 17(6):e13825. PubMed ID: 38808543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
    Budde LE; Assouline S; Sehn LH; Schuster SJ; Yoon SS; Yoon DH; Matasar MJ; Bosch F; Kim WS; Nastoupil LJ; Flinn IW; Shadman M; Diefenbach C; O'Hear C; Huang H; Kwan A; Li CC; Piccione EC; Wei MC; Yin S; Bartlett NL
    J Clin Oncol; 2022 Feb; 40(5):481-491. PubMed ID: 34914545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
    Bock AM; Nowakowski GS; Wang Y
    Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
    Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
    J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
    Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
    EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
    Goebeler ME; Bargou R
    Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity.
    Li J; Piskol R; Ybarra R; Chen YJ; Li J; Slaga D; Hristopoulos M; Clark R; Modrusan Z; Totpal K; Junttila MR; Junttila TT
    Sci Transl Med; 2019 Sep; 11(508):. PubMed ID: 31484792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD47/SIRPα blocking enhances CD19/CD3-bispecific T cell engager antibody-mediated lysis of B cell malignancies.
    Xu L; Wang S; Li J; Li B
    Biochem Biophys Res Commun; 2019 Feb; 509(3):739-745. PubMed ID: 30611570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a minimal physiologically-based pharmacokinetic/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting bispecific agents in humans.
    Jiang X; Chen X; Jaiprasart P; Carpenter TJ; Zhou R; Wang W
    Eur J Pharm Sci; 2020 Apr; 146():105260. PubMed ID: 32058058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody.
    Xiong D; Xu Y; Liu H; Peng H; Shao X; Lai Z; Fan D; Yang M; Han J; Xie Y; Yang C; Zhu Z
    Cancer Lett; 2002 Mar; 177(1):29-39. PubMed ID: 11809528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas.
    Schuster SJ; Huw LY; Bolen CR; Maximov V; Polson AG; Hatzi K; Lasater EA; Assouline SE; Bartlett NL; Budde LE; Matasar MJ; Koeppen H; Piccione EC; Wilson D; Wei MC; Yin S; Penuel E
    Blood; 2024 Feb; 143(9):822-832. PubMed ID: 38048694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.
    Zhu M; Wu B; Brandl C; Johnson J; Wolf A; Chow A; Doshi S
    Clin Pharmacokinet; 2016 Oct; 55(10):1271-1288. PubMed ID: 27209293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific antibodies for the treatment of lymphomas: Promises and challenges.
    Schuster SJ
    Hematol Oncol; 2021 Jun; 39 Suppl 1():113-116. PubMed ID: 34105818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
    Sun LL; Ellerman D; Mathieu M; Hristopoulos M; Chen X; Li Y; Yan X; Clark R; Reyes A; Stefanich E; Mai E; Young J; Johnson C; Huseni M; Wang X; Chen Y; Wang P; Wang H; Dybdal N; Chu YW; Chiorazzi N; Scheer JM; Junttila T; Totpal K; Dennis MS; Ebens AJ
    Sci Transl Med; 2015 May; 7(287):287ra70. PubMed ID: 25972002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mosunetuzumab: First Approval.
    Kang C
    Drugs; 2022 Jul; 82(11):1229-1234. PubMed ID: 35947358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.